RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma - PubMed
7 hours ago
- #Pancreatic Cancer
- #Chemoresistance
- #RARRES1
- RARRES1 identifies a chemoresistant, immune-cold malignant epithelial subpopulation in pancreatic ductal adenocarcinoma (PDAC).
- This subpopulation is enriched in progressive disease and liver metastasis, showing disrupted immune cell communication and increased regulatory T cells.
- The subcluster exhibits activated oncogenic pathways, multi-drug resistance, higher tumor mutational burden, and frequent KRAS mutations.
- RARRES1 is upregulated in gemcitabine-resistant cells and serves as a pan-cancer biomarker for poor prognosis.
- The study suggests RARRES1 as a pivotal regulator of therapy resistance and immune exclusion in PDAC.